CDK4 and breast carcinoma: Both studies reported no increase in the rates of apoptosis, which is similar to the outcome of combining cell cycle inhibitors (either CDK4/6i or endocrine therapy) with MDM2i in ER+ breast cancer models (29, 46), but also no evidence of any combined effect beyond additivity at best.